High Susceptibility Antibiotics Reduce Readmission Rates for UTIs
|This article is part of MPR's coverage of IDWeek 2018, taking place in San Francisco, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2018.|
SAN FRANCISCO — The use of a moderate to low susceptibility antibiotic to treat a urinary tract infection (UTI) may result in a 1.74-fold increase in the odds of an emergency department readmission within 30 days for another UTI, according to a study presented at the IDWeek in San Francisco, CA, October 3-7, 2018.
This study evaluated the creation of an antimicrobial stewardship program to define the community-specific urine antibiogram and categorize antibiotic therapy into high susceptible antibiotics (≥90%) and moderate to low susceptible antibiotics (<90%). Researchers retrospectively analyzed 594 patients who tested positive on a urine culture in the emergency department. Information was collected on the type of urine pathogen present, whether the patient received a high susceptibility or moderate to low susceptibility antibiotic, and if the patient was readmitted for another UTI 30 days after discharge.
Patients who received moderate to low susceptibility antibiotics (44.9%) had a higher 30-day readmission rate when compared with patients who received high susceptibility antibiotics (14.2% vs 7.95%, respectively; P=.014). The adjusted odds ratio for readmission was 1.74 (95% CI, 1.01-2.99; P=.047).
The researchers concluded that creating an antimicrobial stewardship program with a community specific urine antibiogram “may be a useful tool in reduction of 30 day readmission rates” in patients with UTIs who are treated in the emergency department.
|Visit MPR's conference section for continuous coverage live from IDWeek 2018.|
Lee S, Jones S, Casapao AM. Empiric antibiotic therapy and readmission rate in patients with urinary tract infection. Poster presented at: 2018 IDWeek Annual Meeting; Oct. 3-7, 2018; San Francisco, CA. Abstract 46.